Tacrolimus dose could be individualized according to CYP3A5 genotype
This article has no abstract so we have provided the first paragraph of the full text.
As tacrolimus has a narrow therapeutic index and variable pharmacokinetics, it is difficult to achieve effective blood concentrations in all patients. Variability could be due, in part, to the existence of different forms of the CYP3A5 enzyme, which is involved in tacrolimus metabolism. Patients homozygous for the CYP3A5*3 allele (a single nucleotide A>G polymorphism in intron 3 of CYP3A5) lack CYP3A5 activity. Such activity requires the presence of at least one CYP3A5*1 allele.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
